These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 17516390

  • 1. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy.
    Ingram PR, Howman R, Leahy MF, Dyer JR.
    Clin Infect Dis; 2007 Jun 15; 44(12):e115-7. PubMed ID: 17516390
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Alemtuzumab in peripheral T-cell malignancies.
    Dearden C.
    Cancer Biother Radiopharm; 2004 Aug 15; 19(4):391-8. PubMed ID: 15453953
    [Abstract] [Full Text] [Related]

  • 6. The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.
    Thachil J, Jadhav V, Gautam M, McKew S, Arumainathan A, Collins D, Smyth C, Harper J, Pettitt A.
    Br J Haematol; 2007 Aug 15; 138(4):559-60. PubMed ID: 17587337
    [No Abstract] [Full Text] [Related]

  • 7. Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature.
    Bassetti M, Repetto E, Mikulska M, Miglino M, Clavio M, Gobbi M, Righi E, Viscoli C.
    J Chemother; 2009 Apr 15; 21(2):211-4. PubMed ID: 19423476
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
    Chaar BT, Petruska PJ.
    Am J Hematol; 2007 May 15; 82(5):417. PubMed ID: 17160995
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
    Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WE, Willemze R, Catovsky D.
    J Clin Oncol; 1997 Jul 15; 15(7):2667-72. PubMed ID: 9215839
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.
    Abbi KK, Rizvi SM, Sivik J, Thyagarajan S, Loughran T, Drabick JJ.
    Leuk Res; 2010 Jul 15; 34(7):e154-6. PubMed ID: 20362332
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
    Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, Haslbauer F, Demirtas D, Grossschmidt P, Tatzreiter G, Gastl G, Greil R, Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia.
    Cancer; 2006 Nov 15; 107(10):2408-16. PubMed ID: 17054106
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab.
    Schützinger C, Gaiger A, Thalhammer R, Vesely M, Fritsche-Polanz R, Schwarzinger I, Ohler L, Simonitsch-Klupp I, Reinhard F, Jäger U.
    Leukemia; 2005 Nov 15; 19(11):2005-8. PubMed ID: 16193089
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.